- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07635849
RANDOMIZED CLINICAL TRIAL OF ARTIFICIAL TEARS WITH AND WITHOUT PRESERVATIVES IN PATIENTS WITH DRY EYE DISEASE
3. juni 2026 opdateret af: Damodar Sharma, Pokhara Academy of Health Sciences, Western Regional Hospital
Comparative Effectiveness of Artificial Tears With and Without Preservatives in Patients With Dry Eye Disease: A Randomized Clinical Trial
Dry Eye Disease (DED) is a common, chronic ocular surface disorder characterized by tear film instability, ocular discomfort, and visual disturbance.
Artificial tears are the first-line treatment for DED; however, many formulations contain preservatives such as benzalkonium chloride (BAK) and stabilized oxychloro complex (SOC) which may cause ocular surface toxicity with long-term use.
Preservative-free artificial tears are considered safer alternatives, but comparative clinical evidence from Nepal is limited.
This study aims to compare the clinical efficacy and safety of preservative-free versus preserved carboxymethylcellulose (CMC) artificial tears in patients with Dry Eye Disease.
This will be a hospital-based, randomized, double-blinded controlled clinical trial conducted in the ophthalmology outpatient department of a tertiary care hospital in Nepal.
A total of 80 adult patients diagnosed with Dry Eye Disease will be enrolled and randomly allocated in a 1:1 ratio to receive either preservative-free CMC artificial tears or preserved CMC artificial tears for a duration of eight weeks.
Participant, investigators, outcome assessors and data analysts will remain blinded to minimize assessment bias.
Baseline assessments will include the Ocular Surface Disease Index (OSDI) questionnaire, Tear Film Break-Up Time (TBUT), Schirmer's test (without anesthesia), and corneal fluorescein staining.
These outcomes will be reassessed at four and eight weeks.
Safety and tolerability will be evaluated by documenting patient-reported adverse effects.
Data will be analyzed using appropriate statistical methods, with a p-value of less than 0.05 considered statistically significant.
The study is expected to demonstrate superior safety and improved ocular surface outcomes with preservative-free artificial tears compared to preserved formulations.
Findings from this research will provide local evidence to guide rational prescribing practices and improve the management of Dry Eye Disease in Nepal.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
80
Fase
- Fase 4
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Damodar Sharma, MBBS, MD
- Telefonnummer: +977-9856022583
- E-mail: damodars@outlook.com
Undersøgelse Kontakt Backup
- Navn: Jamuna Gurung, MBBS, MD
- Telefonnummer: +977-9860314317
- E-mail: jamunaorama@gmail.com
Studiesteder
-
-
Gandaki
-
Pokhara, Gandaki, Nepal, 33700
- Pokhara Academy of Health Sciences
-
Kontakt:
- Phanindra Prasad Poudel, Msc, PhD
- Telefonnummer: +977-9846115569
- E-mail: poudelpha@gmail.com
-
Underforsker:
- Swikriti Shrestha, MBBS, MD
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Age ≥18 years
- Clinical diagnosis of Dry Eye Disease (OSDI >13 and TBUT <10 seconds)
- Willingness to provide written informed consent
Exclusion Criteria:
- Contact lens use
- Active ocular infection or inflammation
- History of ocular surgery within the past 6 months
- Use of systemic immunosuppressive therapy
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Patients with DED receiving CMC with preservative
40 patients will receive drops in the eye
|
A total of 40 adult patients diagnosed with Dry Eye Disease will be enrolled and randomly allocated in a 1:1 ratio to receive preserved CMC artificial tears for a duration of eight weeks.
Andre navne:
|
|
Aktiv komparator: Patients with DED receiving CMC without preservative
40 patients will receive drops in the eye
|
A total of 40 adult patients diagnosed with Dry Eye Disease will be enrolled and randomly allocated in a 1:1 ratio to receive preservative-free CMC artificial tears for a duration of eight weeks.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Ocular Surface Disease Index (OSDI) Score
Tidsramme: From enrollment to the end of treatment at 8 weeks
|
This is a validated questionnaire that serves as the primary endpoint to evaluate and compare the improvement in dry eye symptom severity between the two groups.
|
From enrollment to the end of treatment at 8 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Tear Film Break-Up Time (TBUT)
Tidsramme: From enrollment to the end of treatment at 8 weeks
|
A clinical test used to assess changes in tear film stability
|
From enrollment to the end of treatment at 8 weeks
|
|
Schirmer's Test (without anesthesia)
Tidsramme: From enrollment to the end of treatment at 8 weeks
|
A test used to evaluate aqueous tear production by measuring wetting length on a filter paper strip
|
From enrollment to the end of treatment at 8 weeks
|
|
Corneal Fluorescein Staining Score
Tidsramme: From enrollment to the end of treatment at 8 weeks
|
An assessment used to evaluate and grade epithelial damage or defects on the ocular surface
|
From enrollment to the end of treatment at 8 weeks
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and Tolerability (Adverse Effects)
Tidsramme: From enrollment to the end of treatment at 8 weeks
|
Patient-reported adverse effects will be systematically documented throughout the trial to evaluate the safety and tolerability of the respective artificial tear formulations
|
From enrollment to the end of treatment at 8 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. juli 2026
Primær færdiggørelse (Anslået)
1. januar 2027
Studieafslutning (Anslået)
1. marts 2027
Datoer for studieregistrering
Først indsendt
3. juni 2026
Først indsendt, der opfyldte QC-kriterier
3. juni 2026
Først opslået (Faktiske)
9. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
9. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
3. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CTRL-DEDCMC-PRVFREE/WITHPRV
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Tørre øjne (DED)
-
Olympic Ophthalmics, Inc.RekrutteringMicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye SyndromeForenede Stater
Kliniske forsøg med Carboxy methyl cellulose
-
Shahida Islam Medical ComplexAfsluttetPostpartum anæmiPakistan
-
BiogenAfsluttetSund og rask | Nedsat leverfunktionForenede Stater
-
BiogenTrukket tilbageDiabetes mellitus, type 2 | Nyreinsufficiens, kronisk
-
BiogenAfsluttetSund og raskForenede Stater
-
BiogenAfsluttet
-
Sohag UniversityAfsluttet
-
BiogenTrukket tilbageDiabetes mellitus, type 2 | Nyreinsufficiens, kronisk
-
BiogenAfsluttetDiabetes mellitus, type 2 | Nyreinsufficiens, kronisk
-
National Cancer Institute (NCI)LantheusAktiv, ikke rekrutterendeProstatakræftForenede Stater